Chiao‐En Wu

1.4k total citations
92 papers, 933 citations indexed

About

Chiao‐En Wu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Chiao‐En Wu has authored 92 papers receiving a total of 933 indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 32 papers in Surgery. Recurrent topics in Chiao‐En Wu's work include Lung Cancer Treatments and Mutations (17 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers) and Gastric Cancer Management and Outcomes (11 papers). Chiao‐En Wu is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (15 papers) and Gastric Cancer Management and Outcomes (11 papers). Chiao‐En Wu collaborates with scholars based in Taiwan, United Kingdom and United States. Chiao‐En Wu's co-authors include Chun‐Nan Yeh, John Lunec, John Wen‐Cheng Chang, Jen‐Shi Chen, Shang‐Yu Wang, Wen‐Kuan Huang, Ming‐Huang Chen, Penny E. Lovat, Chin‐Yuan Tzen and Wen‐Chi Chou and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Chiao‐En Wu

83 papers receiving 923 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chiao‐En Wu Taiwan 17 499 289 280 262 154 92 933
Maria Ignez Braghiroli Brazil 14 583 1.2× 210 0.7× 302 1.1× 230 0.9× 147 1.0× 58 901
Nikolaos Charalampakis Greece 12 511 1.0× 270 0.9× 305 1.1× 213 0.8× 163 1.1× 42 988
Seung‐Hoon Beom South Korea 17 459 0.9× 150 0.5× 361 1.3× 230 0.9× 110 0.7× 69 901
Byoung Yong Shim South Korea 18 596 1.2× 232 0.8× 359 1.3× 248 0.9× 182 1.2× 110 1.0k
Antonia Strippoli Italy 17 532 1.1× 134 0.5× 438 1.6× 328 1.3× 176 1.1× 66 1.1k
Jingshan Ho Singapore 7 358 0.7× 220 0.8× 488 1.7× 307 1.2× 111 0.7× 17 924
Y-J. Bang South Korea 20 720 1.4× 352 1.2× 559 2.0× 276 1.1× 162 1.1× 54 1.3k
Sarah Slater United Kingdom 14 527 1.1× 170 0.6× 650 2.3× 320 1.2× 61 0.4× 38 1.1k
Cuong Duong Australia 17 408 0.8× 359 1.2× 485 1.7× 480 1.8× 238 1.5× 50 1.2k
Thomas Cerny Switzerland 16 508 1.0× 229 0.8× 443 1.6× 182 0.7× 91 0.6× 28 966

Countries citing papers authored by Chiao‐En Wu

Since Specialization
Citations

This map shows the geographic impact of Chiao‐En Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chiao‐En Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chiao‐En Wu more than expected).

Fields of papers citing papers by Chiao‐En Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chiao‐En Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chiao‐En Wu. The network helps show where Chiao‐En Wu may publish in the future.

Co-authorship network of co-authors of Chiao‐En Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Chiao‐En Wu. A scholar is included among the top collaborators of Chiao‐En Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chiao‐En Wu. Chiao‐En Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chen, Hsiao‐Ling, et al.. (2025). Modeling brain metastases in cost effectiveness analysis of atezolizumab for extensive stage small cell lung cancer. Scientific Reports. 15(1). 39298–39298.
3.
4.
Chang, John Wen‐Cheng, Jia‐Juan Hsieh, Chih‐Yu Tsai, et al.. (2024). Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer. Biomedical Journal. 47(5). 100698–100698. 14 indexed citations
5.
Hsu, Ping‐Chih, et al.. (2024). Synergistic effects of MK-1775 and gemcitabine on cytotoxicity in non-small cell lung cancer. Heliyon. 10(22). e40299–e40299.
6.
Liu, Chi‐Hung, et al.. (2023). Coexisting Nodular Sclerosis Hodgkin Lymphoma and Kimura’s Disease: A Case Report and Literature Review. International Journal of Molecular Sciences. 24(8). 7666–7666.
7.
Huang, Wen‐Kuan, Pei‐Hua Peng, Shih‐Ming Jung, et al.. (2023). PLK1 and its substrate MISP facilitate intrahepatic cholangiocarcinoma progression by promoting lymphatic invasion and impairing E-cadherin adherens junctions. Cancer Gene Therapy. 31(2). 322–333. 2 indexed citations
8.
Yeh, Chun‐Nan, et al.. (2023). Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer. Biomedicine & Pharmacotherapy. 166. 115389–115389. 5 indexed citations
9.
Wu, Chiao‐En, Shih‐Chiang Huang, Sheng‐Hsuan Lin, et al.. (2023). Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation. International Journal of Biological Sciences. 19(9). 2772–2786. 7 indexed citations
10.
Yeh, Chun‐Nan, et al.. (2023). A Potential Association of Zinc Deficiency and Tyrosine Kinase Inhibitor-Induced Hand-Foot Skin Reaction. Biological Trace Element Research. 201(12). 5540–5545. 4 indexed citations
11.
Tsai, Pei‐Shan, et al.. (2022). Plasmapheresis for a Patient with Catatonia and Systemic Lupus Erythematosus: A Case Report and Literature Review. Journal of Clinical Medicine. 11(22). 6670–6670. 2 indexed citations
12.
Huang, Wen‐Kuan, Chiao‐En Wu, Shang‐Yu Wang, et al.. (2022). Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges. Current Treatment Options in Oncology. 23(9). 1303–1319. 12 indexed citations
13.
Wu, Chiao‐En, Wen‐Kuan Huang, Wen‐Chi Chou, et al.. (2021). Establishment of a Pretreatment Nomogram to Predict the 6-Month Mortality Rate of Patients with Advanced Biliary Tract Cancers Undergoing Gemcitabine-Based Chemotherapy. Cancers. 13(13). 3139–3139. 4 indexed citations
14.
15.
Chang, Yu‐Chan, Chiao‐En Wu, Dennis Shin-Shian Hsu, et al.. (2021). Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. Biomedicines. 9(8). 885–885. 4 indexed citations
16.
Wu, Chiao‐En, Da‐Wei Yeh, Wen‐Kuan Huang, et al.. (2020). Chromosomal Instability May Not Be a Predictor for Immune Checkpoint Inhibitors from a Comprehensive Bioinformatics Analysis. Life. 10(11). 276–276. 12 indexed citations
17.
Chen, Ming‐Huang, Chi‐Tung Cheng, Ren‐Chin Wu, et al.. (2016). ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients. Clinical Cancer Research. 22(16). 4225–4235. 48 indexed citations
18.
Wu, Chiao‐En, Shin‐Cheh Chen, Hsien‐Kun Chang, et al.. (2015). Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years. Journal of the Formosan Medical Association. 115(4). 249–256. 4 indexed citations
19.
Tang, Siew Tzuh, Jen‐Shi Chen, Wen-Chi Chou, et al.. (2015). Prevalence of severe depressive symptoms increases as death approaches and is associated with disease burden, tangible social support, and high self-perceived burden to others. Supportive Care in Cancer. 24(1). 83–91. 21 indexed citations
20.
Wu, Chiao‐En, Chia‐Hsun Hsieh, Cheng-Jen Chang, et al.. (2013). Prognostic factors for Taiwanese patients with cutaneous melanoma undergoing sentinel lymph node biopsy. Journal of the Formosan Medical Association. 114(5). 415–421. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Ignez Braghiroli Breakdown of academic impact, for papers by Nikolaos Charalampakis Breakdown of academic impact, for papers by Seung‐Hoon Beom Breakdown of academic impact, for papers by Byoung Yong Shim Breakdown of academic impact, for papers by Antonia Strippoli Breakdown of academic impact, for papers by Jingshan Ho Breakdown of academic impact, for papers by Y-J. Bang Breakdown of academic impact, for papers by Sarah Slater Breakdown of academic impact, for papers by Cuong Duong Breakdown of academic impact, for papers by Thomas Cerny
Rankless by CCL
2026